To view the full abstract click the title of the presentation.
Slides for all of the abstracts highlighted are featured in the written review. This is available for download under the reviews tab.
Our themed podcasts will be available here - please check back soon.
JAK inhibitors are advancing treatment and management options across immune-mediated inflammatory diseases. To understand the science of cytokine signalling and the effects of blocking different pathways, join us for this symposium at the 2021 EULAR annual conference. The session will explain the JAK-STAT pathway and describe the mechanism of action of agents – both those approved and under investigation. We will examine the clinical outcomes of JAK inhibition and invite you to submit your own questions in a live interactive discussion session.
This symposium is independently developed by the Cytokine Signalling Forum and sponsored by Lilly.
Welcome and Introduction
Cytokine Signalling Pathways: What are They and How Do They Work?
Targeting the JAK-STAT Pathway: What are the Immune-pathologic Consequences?
Mechanisms of JAK inhibition: Current Results, Future Perspectives
Summary and Close
Professor of Clinical Medicine; Director of Leeds Biomedical Research Centre in University of Leeds
Professor Emery is the Arthritis Research UK Professor of Rheumatology, University of Leeds, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Professor Emery was Cambridge undergraduate 1971(Churchill College), did clinical training at Guy’s and undertook early specialist training at Guy’s and Brompton. After completing his accreditation in Rheumatology and GIM. he became Head of Rheumatology at Walter & Eliza Hall Institute and Consultant at the Royal Melbourne Hospital in 1985. He returned to the University of Birmingham as a Senior Lecturer in 1987. Since 1995 he has been AR UK Professor of Rheumatology in Leeds and Head of Department (-2018). Leeds under his direction is one of the worlds’ largest and most highly rated centres. Since 2009 he has been Director of the Leeds NIHR Biomedical Research Centre.
Director, NIAMS Intramural Research Program, NIAMS, Bethesda, Maryland, USA
John J. O'Shea, M.D., graduated Phi Beta Kappa with a Bachelor of Science degree from St. Lawrence University, and received a Doctor of Medicine degree from the University of Cincinnati. He then served as an intern and resident in Internal Medicine at the State University of New York Upstate Medical University in Syracuse, New York. Dr O'Shea joined the National Institutes of Health (NIH) in 1981 for subspecialty training in Allergy and Immunology in the National Institute of Allergy and Infectious Diseases. He did additional postdoctoral work in the Cell Biology and Metabolism Branch in the National Institute of Child Health and Human Development. Dr O’Shea is board certified in Internal Medicine and Allergy and Immunology.
He moved to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 1994 as Chief of the Lymphocyte Cell Biology Section of the Arthritis and Rheumatism Branch. He was appointed Chief of the Molecular Immunology and Inflammation Branch in 2002 and became Scientific Director and Director of the NIAMS Intramural Research Program in 2005.
Dr O'Shea has served on the editorial boards of multiple journals, including: Immunity, Journal of Experimental Medicine, Journal of Biological Chemistry, Journal of Immunology, and Blood. He has been an invited lecturer at numerous universities and international meetings in the U.S., Canada, Europe, and Asia. His area of scientific interest is cytokine signal transduction, dissecting the role of Jaks and Stats family transcription in immunoregulation. Dr O'Shea and his colleagues cloned the tyrosine kinase, JAK3, and demonstrated its role in pathogenesis of severe combined immunodeficiency.
Newcastle University Translational and Clinical Research Institute, Newcastle-upon-Tyne, UK; Associate Medical Director (Research), Newcastle upon Tyne Hospitals NHS Foundation Trust
John Isaacs is Professor of Clinical Rheumatology and Director of Therapeutics North East at Newcastle University and Associate Medical Director for Research and Consultant Rheumatologist at Newcastle upon Tyne Hospitals NHS Foundation Trust. Over the past 25 years, his work has focused on the potential of novel immunotherapies to treat rheumatoid arthritis (RA), ranging from target identification to early- and late-stage clinical trials.
Professor Isaacs runs a research group focussed on therapeutic tolerance induction. His team has pioneered tolerogenic dendritic cell therapy in inflammatory arthritis patients. In 2019 he became a National Institute for Health Research Senior Investigator and is past Chair of the Scientific Committee of the European League Against Rheumatism.
As Associate Medical Director for Research at Newcastle Hospitals he has developed a research strategy focussed on embedding research into everyday patient care. He is also Research Director of Newcastle Health Innovation Partners (Newcastle’s Academic Health Science Centre), where he is focussed on ensuring research discoveries lead to innovation, to improve the health and wealth of the regional population and beyond.
Head of Department of Internal Medicine, Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Germany
Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Join us at the Cytokine Signalling Forum’s symposium at the EULAR 2021 annual conference. Here our expert faculty will review the most recent findings and advice on the management of patients during the COVID-19 pandemic. We will also discuss the changes in patient management. Specifically focusing on the increased utilisation of telemedicine.
This symposium programme is provided by the CSF and supported by an educational grant from AbbVie.
Welcome, Introduction, and Objectives
COVID-19 Global Registries: What have we Learned?
Treatment Guidance for Patients with RMD in the COVID-19 era
COVID-19 Vaccination for Patients with RMD: Experience from the UK
Summary and Close
Director & Professor of Medicine, RJ Fasenmyer Centre for Clinical Immunology, Cleveland Clinic Foundation, Ohio, USA
Leonard Calabrese is a Professor of Medicine, Vice Chair of the Cleveland Clinic’s Department of Rheumatic and Immunologic Diseases and the Co-director of the Centre for Vasculitis Care and Research. He also serves as Director of the RJ Fasenmyer Centre for Clinical Immunology at the Cleveland Clinic. He also holds appointments in the Department of Infectious Diseases and the Wellness Institute.
He is a graduate of the Kansas City University of Medicine and Biosciences. Completed his internal medicine training at the Cleveland Clinic Foundation in Ohio, followed by a fellowship in rheumatic and immunologic disease. Professor Calabrese has received numerous awards, including honorary Doctorates of Humane Letters from the Kansas City University of Medicine and Biosciences and Alma College and the Leonard Tow Humanitarianism in Medicine award from the Arnold P Goldman MD Foundation.
He has particular interest in vascular inflammatory disease of the central nervous system, primary and secondary immunodeficiency states and the intersection of infections and autoimmunity. Over the course of his academic research career, Professor Calabrese has authored over 400 publications including book chapters and peer-reviewed journal articles.
Professor of Epidemiology, UK Centre for Epidemiology Versus Arthritis
Professor Hyrich completed her Bachelor of Science and Medical degree at the University of Manitoba in Canada. Following this, she trained in Internal Medicine in Winnipeg, Canada and completed a Fellowship in Rheumatology at the University of Toronto. She was awarded her PhD in 2005 subsequently working as a CIHR Research Fellow at the Arthritis Research UK Epidemiology Unit in Manchester. She is now Professor of Epidemiology at the University of Manchester and an Honorary Rheumatology Consultant at the Manchester Royal Infirmary.
Her main research interests centre on outcomes in inflammatory arthritis, with a focus on pharmacoepidemiology. Professor Hyrich is a member of the EULAR registries group and the chief investigator for the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis as well as two national biologic registers for Juvenile Idiopathic Arthritis; the Versus Arthritis funded Safety of Biologics in Children with Rheumatic Diseases and the BSPAR Etanercept JIA Register. Professor Hyrich was instrumental in the collaboration of the global COVID-19 registers for patients with rheumatic disease.
Professor in Rheumatology, Academic Medical Centre (AMC), University of Amsterdam, the Netherlands; Clinical Rheumatologist and Chair of the Division of Rheumatology, Zuyderland Medical Centre, Heerlen, the Netherlands
Robert Landewé obtained his medical degree at the University of Maastricht, the Netherlands, in 1990, and his PhD in 1994. Robert Landewé is a board-certified rheumatologist since 1999.
In 1999, he was appointed as a staff rheumatologist, and since 2008 as a professor of rheumatology at the department of rheumatology in the Maastricht University Hospital, the Netherlands, until April 2011. From April 2011 onwards he has a part-time staff position as professor of rheumatology in the Academic Medical Centre / University of Amsterdam. He further works as a consultant in rheumatology at the department of rheumatology in the Zuyderland Medical Centre in Heerlen, the Netherlands.
His major research interests include the assessment and prediction of outcome in rheumatic diseases, with a focus on statistical modelling, and with a special interest in spondyloarthritis. He has been involved in many clinical trials in the field of RA, PsA and axial spondyloarthritis as a clinical (principal) investigator, as a reader of radiographs and MRIs and as an advisor in steering committees.
Professor Landewé was president of the Assessment in SpondyloArthritis international Society [ASAS] between 2012 and 2018, and a previous member of the OMERACT executive board. He served as a member of the board of the Dutch Society of Rheumatology (quality of care) from 2012 till 2018.
Professor Landewé has published over 380 papers in the international literature, as well as many chapters in all leading rheumatology textbooks. He is a regular reviewer for all major rheumatology journals and for journals in medicine and serves on the editorial board of the Annals of Rheumatic Diseases.
Honorary Chair of Clinical Rheumatology, University of Southampton, UK
Professor Christopher Edwards is Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology, University Hospital Southampton NHS Foundation Trust within Medicine at the University of Southampton. He graduated with honors from King's College London and trained at the Hammersmith and St George's Hospitals in London. He was a registrar for Professor Graham Hughes at the St Thomas' Hospital lupus unit and then undertook a period of research as a lecturer at the Kennedy Institute of Rheumatology at Imperial College under the supervision of Professor Ravinder Maini. He moved to Southampton in 2001 after working for a year as a rheumatology consultant at Tan Tock Seng Hospital in Singapore.
Professor Edwards is a clinical rheumatologist with research interests and expertise in the epidemiology and treatment of inflammatory rheumatic diseases including rheumatoid arthritis, lupus, psoriatic arthritis, and ankylosing spondylitis.
He is a member of international committees working to produce guidelines for the best management of rheumatic diseases, leading a systematic review of guidelines for the use of radiology in the diagnosis and management of rheumatoid arthritis for EULAR. With expertise in the planning and delivery of trials in this area, including early-stage trials, Professor Edwards has developed strong local and international partnerships with clinical and academic colleagues, centred on his role as clinical lead of the Southampton Musculoskeletal Research Unit. Professor Edwards also serves as Associate Editor for Rheumatology, and on the editorial board of Lupus.